evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,703 questions · 15,007 findings · 1,416 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2,881 · 19.2%GRADE not reported 1,551 · 10.3%Very low 3,111 · 20.7%Low 3,881 · 25.9%Moderate 2,669 · 17.8%High 914 · 6.1%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Systemic aminocaproic acid vs placebo

Final visual acuity 20/40 or better at resolution of hyphema · people with traumatic hyphema

Systemic aminocaproic acid showed no clear difference in final visual acuity 20/40 or better at resolution of hyphema compared with placebo (low certainty).

1 finding from 1 review

Systemic aminocaproic acid vs placebo

Adverse event nausea and vomiting (0 to 24 hours) · people with traumatic hyphema

Systemic aminocaproic acid probably leads to higher adverse effects: nausea or vomiting compared with placebo (moderate certainty).

1 finding from 1 review

Topical aminocaproic acid vs placebo

Short‐term visual acuity 20/40 or better ≤ 2 weeks after treatment · people with traumatic hyphema

Topical aminocaproic acid showed no clear difference in short‐term visual acuity 20/40 or better ≤ 2 weeks after treatment compared with placebo (low certainty).

1 finding from 1 review

Summary of findings table ‐ Recombinant activated factor VII vs placebo/open control

Death or dependence (mRS 4 to 6) at day 90 · adults with acute spontaneous intracerebral haemorrhage

Summary of findings table ‐ Recombinant activated factor VII showed no clear difference in death or dependence (mRS 4–6) compared with placebo/open control (low certainty).

1 finding from 1 review

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs placebo/open control

All serious adverse events · adults with acute spontaneous intracerebral haemorrhage

Summary of findings table ‐ Antifibrinolytic drug(s) showed no clear difference in all serious adverse events compared with placebo/open control (high certainty).

1 finding from 1 review

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs placebo/open control

Death from any cause · adults with acute spontaneous intracerebral haemorrhage

Summary of findings table ‐ Antifibrinolytic drug(s) showed no clear difference in death from any cause compared with placebo/open control (high certainty).

1 finding from 1 review

Summary of findings table ‐ Recombinant activated factor VII vs placebo/open control

Intracerebral haemorrhage expansion by 24 hours · adults with acute spontaneous intracerebral haemorrhage

Summary of findings table ‐ Recombinant activated factor VII showed no clear difference in intracerebral haemorrhage expansion by 24 hours compared with placebo/open control (low certainty).

1 finding from 1 review

Summary of findings table ‐ Recombinant activated factor VII vs placebo/open control

All serious adverse events · adults with acute spontaneous intracerebral haemorrhage

It is very uncertain whether summary of findings table ‐ Recombinant activated factor VII changes all serious adverse events compared with placebo/open control (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Recombinant activated factor VII vs placebo/open control

Death from any cause · adults with acute spontaneous intracerebral haemorrhage

Summary of findings table ‐ Recombinant activated factor VII showed no clear difference in death from any cause compared with placebo/open control (moderate certainty).

1 finding from 1 review

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs placebo/open control

Death or dependence (mRS 4 to 6) at day 90 · adults with acute spontaneous intracerebral haemorrhage

Summary of findings table ‐ Antifibrinolytic drug(s) showed no clear difference in death or dependence (mRS 4–6) compared with placebo/open control (high certainty).

1 finding from 1 review

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs placebo/open control

Intracerebral haemorrhage expansion by 24 hours · adults with acute spontaneous intracerebral haemorrhage

Summary of findings table ‐ Antifibrinolytic drug(s) leads to lower intracerebral haemorrhage expansion by 24 hours compared with placebo/open control (high certainty).

1 finding from 1 review